Global Age Related Macular Degeneration Amd Disease Anti Vegf Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2022 –2029 |
 Taille du marché (année de référence) |
USD 13,677.02 Million |
 Taille du marché (année de prévision) |
USD 22,951.90 Million |
 TCAC |
% |
| Principaux acteurs du marché |
|
>Maladie mondiale de dégénérescence maculaire liée à l'âge (DMLA) - Marché anti-VEGF, par type (DMLA sèche et DMLA humide), utilisateur final (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire , soins de santé à domicile et autres), canal de distribution (appel d'offres direct et ventes au détail) - Tendances et prévisions de l'industrie jusqu'en 2031.
Maladie de dégénérescence maculaire liée à l'âge (DMLA) - Analyse et perspectives du marché des anti-VEGF
La dégénérescence maculaire liée à l'âge (DMLA) est une maladie oculaire qui peut s'aggraver avec le temps. Elle est la principale cause de perte de vision grave et permanente chez les personnes de plus de 60 ans. Le vieillissement est l'un des facteurs de risque de l'incidence mondiale de la DMLA précoce. La population âgée mondiale augmente à un rythme rapide. L'âge avancé s'accompagne d'une augmentation réciproque du nombre de patients âgés en raison de la prévalence croissante des maladies chroniques. Le diagnostic de la maladie est possible à différents stades, et les tests génétiques et l'imagerie rétinienne font partie des techniques de détection de la maladie. Le diagnostic de la maladie est effectué principalement par des techniques d'imagerie optique et d'autres processus standard.
Il n’existe pas de remède, mais le traitement de la dégénérescence maculaire liée à l’âge (DMLA) peut ralentir la maladie et vous éviter une perte de vision sévère. Le traitement de la dégénérescence maculaire liée à l’âge (DMLA) comprend généralement des médicaments et des produits de diagnostic. Ces techniques sont utilisées pour atteindre la partie endommagée de la rétine et permettent de faciliter le traitement par des thérapies.
Le marché mondial de la maladie de dégénérescence maculaire liée à l'âge (DMLA) - anti VEGF devrait connaître une croissance du marché au cours de la période de prévision de 2024 à 2031. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,8% au cours de la période de prévision de 2024 à 2031 et devrait atteindre 22 951,90 millions USD d'ici 2031 contre 13 677,02 millions USD en 2023.
Le rapport sur le marché mondial de la maladie de dégénérescence maculaire liée à l'âge (DMLA) - anti VEGF fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste. Notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. L'évolutivité et l'expansion commerciale des unités de vente au détail dans les pays en développement de diverses régions et le partenariat avec les fournisseurs pour une distribution sûre des machines et des produits pharmaceutiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (personnalisable pour 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa |
|
Market Players Covered |
Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sulentis, S.A., Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTX, Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., and lonis Pharmaceuticals, among others. |
Market Definition
Anti-VEGF therapy halts abnormal blood vessel growth in the retina, a hallmark of conditions like age-related macular degeneration (AMD). By inhibiting the action of VEGF, these drugs prevent vessel leakage and damage to the central vision area (macula). Administered through eye injections, they slow vision loss and, in some cases, improve sight. This targeted treatment, pivotal in managing AMD, curtails the progression of the disease by impeding the growth of problematic blood vessels in the eye.
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Age-Related Macular Degeneration
The prevalence of vision-threatening diseases, such as glaucoma, cataracts, and age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. They stand out as the leading cause of blindness in the western working-age population. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth, which is driving the market growth.
- Increase in Strategic Initiative by Key Players
Association, the deal is used by the primary player to expand to a different region of the world along with the passing of technology from one player to others, increasing product approval and institutional research.
Various strategic initiatives are undertaken by market players, which involve partnership, product approval, and collaboration among others. These initiatives help them to strengthen their presence in the market and help them to promote market expansion. Moreover, some strategic initiatives increased demand for their products among several customers. Strategic initiatives such as collaboration, agreement, and signing sales agreements are expected to drive the market.
Opportunity
- Increasing Research and Development
Research and development is a prerequisite to modifying the treatment to treat different kinds of patients. The demand for Age-Related Macular Degeneration (AMD) treatment and procedures is increasing in every country. This is why companies are continuously focusing on research and development to successfully provide effective treatment to patients and healthcare workers.
The effects can be seen only for individuals in certain ways, including effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and permanent damage.
Challenges/ Restraints
- High Cost of Treatment and Procedures
The cost of the product plays a major factor in the market. In Age-Related Macular Degeneration (AMD) disease, it is generally observed that they are highly sophisticated, must be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, and with their expensive cost is a major concern in the current healthcare system.
Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage, leading to consuming a significant amount of healthcare resources. Most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment. But, this increases the possibilities and susceptibilities for new complications in the diagnosis, which demands additional healthcare resources and treatment, which is retraining the market growth.
- Limited Access to Treatment
The treatment of a disease directly depends upon the accessibility to the service available for that disease. The treatment rate of various types of Age-Related Macular Degeneration (AMD) diseases falls due to limited access to the hospitals and specialty clinics owing to the low income and limited resources among others.
An interview published in a report in 2019 with the major market players of the drug segment said that they face challenges in providing accessibility to the diagnosis product in the underdeveloped nation. About 285 million individuals worldwide are visually impaired; 80% of these people have curable eye disorders, but limited or no access to adequate care, products, or available technologies improves the prevalence of blindness and decreases the growth of the market.
Recent Developments
- In November 2023, Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology (AAO) annual meeting in San Francisco. This is an investor event where the companies try to attract investors, which helps the company increase the R&D
- In August 2023, Astellas Pharma Inc. announced that IZERVAY (avacincaptad pegol intravitreal solution) will be approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The rate of GA progression at the 12-month primary endpoint was statistically significantly (p<0.01) lower in two Phase 3 clinical trials with the novel complement C5 inhibitor IZERVAY, making it the only approved treatment for GA
- In November 2022, Sylentis, S.A., announced the recruitment of the first patient in a new phase II dose-finding trial with its compound SYL1801 for treating patients with Neovascular Age-Related Macular Degeneration (AMD). This is a randomized, double-blind, phase II trial with three parallel groups in which different dose levels will be administered to each group of subjects. The study has already started and will recruit 90 patients in different centers in several European countries. The trial's primary objective is to evaluate the effect on visual acuity of SYL1801 at all three doses, administered as one drop daily for six weeks in patients with neovascular AMD
- In May 2022, Adverum Biotechnologies, Inc. announced that the company had presented data at the American Society of Gene and Cell Therapy (ASGCT) 2022 annual meeting on the efficacy and safety outcome of ADVM-022 that supported Phase 2 development plans. This results in evaluating the ADVM-022 dose with new enhanced prophylactic steroid regimens in the subsequent clinical trial
- In March 2022, Novartis AG announced that Beovu (brolucizumab) 6 mg had been authorized by the European Commission (EC) to treat visual impairment caused by Diabetic Macular Edoema (DME). Beovu was initially approved by the EC in 20203 to treat wet age-related macular degeneration; the DME indication marks the medication's second approval. The ruling of the European Community (EC) applies to all 27 EU members and Liechtenstein, Iceland, and Norway
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Scope
The global Age-related macular degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Dry AMD
- Wet AMD
On the basis of type, the market is segmented into dry AMD and wet AMD.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Home Healthcare
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
Distribution Channel
- Retail Sales
- Direct Tender
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Regional Analysis/Insights: Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa.
North America is expected to dominate global Age-Related Macular Degeneration (AMD) disease - anti VEGF due to rising prevalence of age-related macular degeneration. The U.S. is expected to dominate the North America region as it has the largest R&D spending globally and offers trade agreements with several countries, making it the largest market for consumer diagnosis and therapy products. China is expected to dominate the Asia-Pacific region due to the mass production of Age-related macular degeneration (AMD) disease - anti VEGF based products and increasing demand from emerging markets and expansion. Germany is expected to dominate the Europe region as it has the emerging reimbursement policies for the treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Analyse du paysage concurrentiel et des parts de marché : Maladie de la dégénérescence maculaire liée à l'âge (DMLA) - Marché mondial des anti-VEGF
Le paysage concurrentiel du marché mondial de la maladie de dégénérescence maculaire liée à l'âge (DMLA) - anti VEGF fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et la portée du produit, la domination des applications, la courbe de vie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Français Certains des principaux acteurs opérant sur le marché mondial de la maladie de dégénérescence maculaire liée à l'âge (DMLA) - anti VEGF sont Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sylentis, SA, Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTx Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., et Ionis Pharmaceuticals, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTERS_
4.3 PRICING ANALYSIS
4.4 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASING GERIATRIC POPULATION
6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE
7.1 OVERVIEW
7.2 WET AMD
7.2.1 MEDICATIONS
7.2.1.1 ANTI-VEGF THERAPY
7.2.1.2 OTHERS
7.2.2 SURGERY
7.3 DRY AMD
8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 U.K.
10.3.4 RUSSIA
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 NETHERLANDS
10.3.8 SWITZERLAND
10.3.9 POLAND
10.3.10 TURKEY
10.3.11 AUSTRIA
10.3.12 HUNGARY
10.3.13 NORWAY
10.3.14 IRELAND
10.3.15 LITHUANIA
10.3.16 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 SINGAPORE
10.4.7 THAILAND
10.4.8 INDONESIA
10.4.9 PHILIPPINES
10.4.10 MALAYSIA
10.4.11 VIETNAM
10.4.12 REST OF ASIA-PACIFIC
10.5 SOUTH AMERICA
10.5.1 BRAZIL
10.5.2 ARGENTINA
10.5.3 PERU
10.5.4 REST OF SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
10.6.1 SOUTH AFRICA
10.6.2 SAUDI ARABIA
10.6.3 U.A.E.
10.6.4 ISRAEL
10.6.5 EGYPT
10.6.6 KUWAIT
10.6.7 REST OF SOUTH AFRICA
11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 REGENERON PHARMACEUTICALS INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAYER AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD)
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.4.5.1 AGREEMENT
16.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ADVERUM BIOTECHNOLOGIES, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOGEN
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 GENSIGHT BIOLOGICS
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 IONIS PHARMACEUTICALS
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 JOHNSON &JOHNSON SERVICES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 KODIAK SCIENCES INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MEIRAGTX LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 OCUGEN, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 OUTLOOK THERAPEUTICS, INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 REGENXBIO INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 SYLENTIS, S.A.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 2 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 43 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 47 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 48 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 49 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 51 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 55 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 59 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 60 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 61 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 65 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 71 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 73 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 78 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 79 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 83 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 84 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 101 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 103 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 107 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 109 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 120 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 121 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 125 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 126 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 127 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 131 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 132 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 137 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 138 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 139 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 141 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 146 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 147 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 151 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 152 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 157 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 158 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 159 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 163 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 164 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 169 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 170 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 175 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 176 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 177 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 181 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 182 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 187 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 188 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 189 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 193 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 201 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 205 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 206 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 207 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 213 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 215 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 SOUTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 SOUTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 219 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 SOUTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 221 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 BRAZIL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 BRAZIL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 225 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 226 BRAZIL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 ARGENTINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 ARGENTINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 231 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 232 ARGENTINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 233 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 PERU WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 235 PERU MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 236 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 237 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 238 PERU RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 239 REST OF SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 240 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 241 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 242 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 245 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 246 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 257 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 258 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 259 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 263 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 264 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 265 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 271 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 275 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 276 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 277 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 281 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 282 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 283 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
Liste des figures
FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID
FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST RATE IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031
FIGURE 15 EUROPE IS THE FASTEST-GROWING MARKET IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET
FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023
FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023
FIGURE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031)
FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE
FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023)
FIGURE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 33 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
